www.drreddys.com

What is Zytorvi?

Zytorvi, our brand name for Toripalimab, is a monoclonal antibody used in cancer treatment, specifically targeting the PD-1 protein on immune cells. It is approved for treating nasopharyngeal carcinoma, both as a first line treatment in combination with chemotherapy and as a single agent in advanced cases.

Need more information? See our downloadable files.

  • Presentation

Storage Conditions

2-8 degrees Celsius (refrigerate), Do not freeze.

Presentation

Vial containing solution for infusion

Route of Administration

Intravenous (IV) (upon prescription only and administered by a healthcare provider)

Indications

Nasopharyngeal Carcinoma (NPC):

NPC is a type of cancer that originates in the nasopharynx, the upper part of the throat behind the nose. It is often associated with Epstein-Barr virus (EBV) infection. Treatment typically involves a combination of chemotherapy, radiation therapy, and immunotherapy.

How Toripalimab works?

Mechanism of Action

Toripalimab is a humanized monoclonal antibody that targets PD-1, a checkpoint protein on T cells that normally helps keep the body's immune responses in check. By blocking PD-1, Toripalimab enhances the immune system's ability to attack cancer cells. This mechanism involves the inhibition of the PD-1/PD-L1 pathway, which is crucial for the immune evasion of cancer cells.

We Meet Global Standards

CDSCO
ISO 9001
INVIMA
SAHPRA

Our News, Stories, and Insights

Read All
  • Publication
  • 12-10-2023

Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study

  • Publication
  • 31-08-2021

A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin (EU) in healthy adult males

  • Publication
  • 17-01-2024

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial

  • Publication
  • 21-12-2020

Safety and tolerability of Peg‑grafeel, a pegfilgrastim, for the prophylactic treatment of chemotherapy‑induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India

See our
Biosimilar Products
Explore
Partnerships